Navigation Links
Study sheds light into the nature of embryonic stem cells
Date:5/25/2010

New insight into what stem cells are and how they behave could help scientists to grow cells that form different tissues.

A study at the University of Edinburgh has shown that embryonic stem cells consist of cells that switch back and forth between precursors of different cell types. This may be linked to their potential to become any cell type in the body.

The findings could help scientists catch embryonic stem cells at exactly the right point when they are primed to differentiate into cells that form specific tissues.

The study indicates that embryonic stem cells are not a single cell type as previously thought, but comprise a mixture of different cell types from the early embryo that can transform themselves from one type to another.

Scientists previously thought that embryonic stem cells were only able to become the embryonic precursors for adult cells, a property known as pluripotency.

The researchers have now found that they can also turn into cells associated with the placenta. These cells known as the primitive endoderm - form the yolk sac that helps provide nutrients to the early embryo.

The study, published in the journal PLoS Biology, also shows that embryonic stem cells are able to alternate and transform themselves between cells that create the primitive endoderm and founder embryonic cells, which will go onto form tissues in the body.

Although cells in early embryonic development switch back and forth between these two different cells, signals received from surrounding cells and the embryonic environment allow them to quickly fix on becoming one specific cell type.

However, in the laboratory embryonic stem cells are grown in a dish away from the embryo and as a result exist in a captured state where their identity does not become fixed.

Scientists hope that better understanding of how embryonic stem cells change will enable them create an environment to encourage growth of specific cells.

Dr Josh Brickman, from the University's Medical Research Council Centre for Regenerative Medicine, said: "This study changes our view of what embryonic stem cells are and how they behave. Knowing that embryonic stem cells can switch between different founder cell types could help us isolate cells at a point in time when they are primed to become specific cells. This could improve the ability to produce specific cells in the laboratory."


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
44-131-650-9836
University of Edinburgh
Source:Eurekalert

Related biology technology :

1. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
2. Carolina Conceptions Announces New Egg Freezing Study to Help Women Preserve their Fertility
3. Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
6. AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
7. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
8. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
9. Chimerix Initiates Phase 1 Study of CMX157
10. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
11. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the US, ... World. Annual estimates and forecasts are provided for the period 2015 ... markets. Market data and analytics are derived from primary and secondary ...
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata Technologies, ... for the homecare industry, including Electronic Visit Verification™ ... expert, Justin Jugs, as Senior Vice President of ... 15 years of homecare experience to Sandata, where ... strategic plans to align Sandata,s suite of solutions ...
Breaking Biology News(10 mins):